NGL Fine Chem Ltd
NGL Fine Chem Q1 FY26: Revenue ₹104.19 Cr, PAT ₹9.24 Cr
Q1 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹104Cr
- +14.3% YoY
- Net profit
- ₹9Cr
- 0% YoY
- Margin
- 11%
- +1 pp YoY
Guidance rank: #34 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on NGL Fine Chem Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1FY26 Revenue from operations: ₹104.19 crores - Year-on-year (YoY) revenue growth: 14.80% - Total income Q1FY26: ₹110.54 crores, YoY growth: 14.38% - EBITDA for Q1FY26: ₹10.97 crores, YoY growt EBITDA for the quarter: ₹10.97 crores, up 73.64% YoY, margin 10.53%, up 388 bps YoY (Page 8) - Operating expenses: ₹93.21 crores (Page 8) - Profit after tax (PAT) for the quarter: ₹9.24 crores, up
From NGL Fine Chem Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1FY26 Revenue from operations: ₹104.19 crores
- Year-on-year (YoY) revenue growth: 14.80%
- Total income Q1FY26: ₹110.54 crores, YoY growth: 14.38%
- EBITDA for Q1FY26: ₹10.97 crores, YoY growth: 17.36%
- EBITDA margin improved by 23 bps YoY to 10.53%
- Volume growth primarily drove topline increase in Q1FY26 (Management Commentary, Page 6)
2 more points from NGL Fine Chem Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what NGL Fine Chem Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Greenfield expansion at Tarapur with ongoing civil construction; invested ₹119.83 crores till Q1FY26.
- Additional capacities of intermediates completed in subsidiary Macrotech; commercial production started.
- Capacity expansion with sufficient capacity to meet demand for new products in pipeline.
- Estimated capex approximately ₹160 crores to be funded through debt and internal accruals.
2 more points from NGL Fine Chem Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what NGL Fine Chem Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what NGL Fine Chem Ltd said on order book & pipeline — free account, 30 seconds.
NGL Fine Chem Ltd — Quarterly revenue & net profit
NGL Fine Chem Ltd Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 104 | 91 | +14.3% | 95 | +9.5% |
| Operating profit (EBITDA) | 11 | 9 | +22.2% | 6 | +83.3% |
| Operating margin | 11% | 10% | +1 pp | 7% | +4 pp |
| Profit before tax | 12 | 12 | 0% | 1 | +1100% |
| Net profit (PAT) | 9 | 9 | 0% | 1 | +800% |
| EPS (₹) | 14.96 | 14.92 | +0.3% | 0.87 | +1619.5% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹159 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What NGL Fine Chem's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- Influx Healthtech (Q1 FY26)
FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26). Key concall takeaways from Influx Healthtech Ltd's Q1 FY26…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
NGL Fine Chem Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were NGL Fine Chem Ltd Q1 FY26 results?
Q1FY26 Revenue from operations: ₹104.19 crores - Year-on-year (YoY) revenue growth: 14.80% - Total income Q1FY26: ₹110.54 crores, YoY growth: 14.38% - EBITDA for Q1FY26: ₹10.97 crores, YoY growt EBITDA for the quarter: ₹10.97 crores, up 73.64% YoY, margin 10.53%, up 388 bps YoY (Page 8) - Operating expenses: ₹93.21 crores (Page 8) - Profit after tax (PAT) for the quarter: ₹9.24 crores, up
What is NGL Fine Chem Ltd share price analysis?
NGL Fine Chem Ltd currently shows a neutral. The stock trades at a P/E of 33.9 with a market cap of ₹1,711 Cr. Investors should review the full earnings analysis for detailed insights.
Is NGL Fine Chem Ltd planning capital expenditure?
Greenfield expansion at Tarapur with ongoing civil construction; invested ₹119.83 crores till Q1FY26.
Keep NGL Fine Chem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.